[Place of hematopoietic stem cell transplantation for very high risk acute myeloblastic leukemia and myelodysplastic syndromes (SFGM-TC)]

Bull Cancer. 2025 Jan;112(1S):S54-S67. doi: 10.1016/j.bulcan.2024.06.016. Epub 2024 Sep 5.
[Article in French]

Abstract

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). However, these transplants are complicated by a high rate of relapse in very high cytogenetic risk or refractory diseases. The benefit of this therapeutic strategy for these serious malignant hemopathies could therefore be reassessed. As part of the 14th workshop for the harmonization of allograft practices organized by the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC) (SFGM-TC) in Lille in September 2023, the role of allograft for very high risk or refractory AML and MDS was challenged after analysis of published studies.

Keywords: Allogreffe de cellules souches hématopoïétiques; Leucémie aiguë myéloblastique; Syndrome myélodysplasique; Very high-risk acute myeloid leukemia; Very high-risk myelodysplastic syndrome.

Publication types

  • Review
  • Consensus Development Conference
  • English Abstract
  • Practice Guideline

MeSH terms

  • Hematopoietic Stem Cell Transplantation* / methods
  • Hematopoietic Stem Cell Transplantation* / standards
  • Humans
  • Leukemia, Myeloid, Acute* / therapy
  • Myelodysplastic Syndromes* / therapy
  • Recurrence
  • Transplantation Conditioning / methods
  • Transplantation Conditioning / standards
  • Transplantation, Homologous / methods
  • Transplantation, Homologous / standards